An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID:
MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
[Corticosterone results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Doxorubicin; [Doxorubicin co-treated with ZFP260 protein] results in increased expression of BCL2L1 protein; BCL2L1 mRNA affects the reaction [Progesterone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; BCL2L1 protein affects the reaction [Corticosterone results in decreased susceptibility to Doxorubicin]; coenzyme Q10 inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein]; Doxorubicin inhibits the reaction [Dexamethasone results in increased expression of BCL2L1 protein]; GHRL protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 mRNA]; Ginkgo biloba extract inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein]; Phenylephrine inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 mRNA]; TNF protein affects the reaction [GHRL protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 mRNA]]
Doxycycline inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein]; Silymarin inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein]
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [Curcumin co-treated with Doxorubicin] affects the expression of BCL2L1 mRNA; BCL2L1 protein inhibits the reaction [BID protein results in increased susceptibility to Doxorubicin]; BCL2L1 protein inhibits the reaction [Sildenafil Citrate results in increased activity of Doxorubicin]; bisphenol A affects the reaction [Doxorubicin affects the expression of BCL2L1 mRNA]; bisphenol A promotes the reaction [Doxorubicin results in increased expression of BCL2L1 protein]; Doxorubicin promotes the reaction [MAPK14 protein results in decreased expression of BCL2L1 protein]; Folic Acid inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 mRNA]; MAP3K20 protein promotes the reaction [Doxorubicin results in decreased expression of BCL2L1 protein modified form]; NFKB1 protein affects the reaction [Doxorubicin results in increased expression of BCL2L1 protein]; pluronic block copolymer p85 inhibits the reaction [Doxorubicin results in increased expression of BCL2L1 mRNA]; Protein Kinase Inhibitors inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein]; Sildenafil Citrate promotes the reaction [Doxorubicin results in decreased expression of BCL2L1 protein]; TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of BCL2L1 protein]
